<DOC>
	<DOC>NCT02615145</DOC>
	<brief_summary>The interferon-free combination regimen of Paritaprevir/r - Ombitasvir with or without Dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions. This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in Germany in a clinical practice patient population.</brief_summary>
	<brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Treatmentnaïve or experienced patients with confirmed CHC, genotype 1 or 4, receiving combination therapy with the interferonfree ABBVIE REGIMEN ± RBV according to standard of care and in line with local label. If RBV is coadministered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy) Patients must voluntarily sign and date a patient authorization to use and/or disclose his/her pseudonymized health data prior to inclusion into the study Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial Adolescents; people not treated according to label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Quality of life</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Observational Study</keyword>
	<keyword>Work-ability</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Ombitasvir+Paritaprevir+Ritonavir</keyword>
	<keyword>Fibrosis</keyword>
</DOC>